Trial of Hydroxychloroquine In Covid-19 Kinetics (THICK)

University of South Alabama (USA)

Status and phase

Terminated

Phase 3

Phase 2

Conditions

Covid 19

Corona Virus Infection

Treatments

Drug: Hydroxychloroquine

Other: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT04353271

[1582736-1]

Details and patient eligibility

About

To test if the medication Hydroxychloroquine will decrease the amount of virus(as measured by PCR) , 7 days after initiation of therapy compared to control patients receiving placebo.

The study design is a randomized (5 days of medication v. 5 days of placebo) clinical trial initiated immediately after diagnosis in ambulatory health care workers at University of South Alabama Health, or in ambulatory USA patients. At 7 days after enrollment another nasopharyngeal swab will be taken to measure if the virus is still present. At 10 weeks we will measure immunity from Covid-19 using a single blood sample. It is a phase 2/3 clinical trial.

Full description

Hydroxychloroquine (HCQ), which is a less toxic derivative of chloroquine (CQ), has been shown to be effective in inhibiting Covid-19 infection in vitro. The evidence from clinical research trials is sparse and has many flaws. Much of the Chinese experience with Chloroquine comes from a letter to the editor and a news briefing/conference held on February 15, 2020. The letter describes experience with more than 100 patients treated with CQ in multicenter clinical trials but the letter provides no quantitative data to back their claims. At least one non-randomized clinical trial has been performed in Europe. Covid-19 infected patients received 10 days of HCQ daily and underwent daily testing of viral loads from nasopharyngeal swabs. The subjects receiving HCQ were much more likely (P<0.02) to clear their viral load than subjects who did not receive HCQ. The study had many flaws, which make the conclusions less valuable than rigorously designed randomized clinical trial. This study is designed as a randomized, blinded trial to either confirm or refute the efficacy of HCQ in early treatment of Covid19 infection to ameliorate disease severity, and reduce viral load.

Enrollment

3 patients

Sex

All

Ages

19 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Symptoms occurring within 3 days prior to patient presenting to USA Facility for PCR nasopharyngeal swab
Nasopharyngeal swab positive for Covid-19 infection and/or exposure and/or symptoms congruent with fever and cough
Male or Female age 19 to 89 years
Able to take oral medications
Patients not requiring hospitalization
Provision of informed consent

Exclusion criteria

Known history of EKG QTc prolongation abnormality
Contraindication or allergy to hydroxychloroquine
Retinal eye disease
Known glucose-6 phosphate dehydrogenase (G-6-PD) deficiency
Known chronic kidney disease, stage 4 or 5 or receiving dialysis
Weight < 40 kg
Current use of: hydroxychloroquine or cardiac medicines of: flecainide, Tambocor; amiodarone, Cordarone, Pacerone; digoxin or Digox, Digitek, Lanoxin; procainamide or Procan, Procanbid, propafenone, Rythmal)
Known hepatic disease (cirrhosis, hepatitis)
Active treatment for cancer (chemotherapy, radiation, surgery within 3 months
On immunosuppressive drugs steroids, antirejection medications.
Recipient of solid organ transplant
Pregnancy/breastfeeding
Past medical history Porphyria (may exacerbate disease)
PMH Psoariasis (can worsen disease)
No access to internet or email
Current suicidal thoughts according to Columbia scale
In the screening process before signing consent, subjects will be asked if they are suicidal. If this response is yes, patients will be excluded from trial and directed to the National Suicide Prevention Lifeline: 1-800-273-8255.